IMR Press / EJGO / Volume 27 / Issue 2 / pii/2006143

European Journal of Gynaecological Oncology (EJGO) is published by IMR Press from Volume 40 Issue 1 (2019). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with S.O.G.

Open Access Case Report

Does raloxifene therapy affect rnarnrnographic breast cancer screening in postrnenopausal patients?

Show Less
1 Department of Obstetrics and Gynecology, Ege University Faculty of Medicine, Izmir, Turkey
2 Department of Radiology, Ege University Faculty of Medicine, Izmir, Turkey
Eur. J. Gynaecol. Oncol. 2006, 27(2), 177–178;
Published: 10 April 2006
Abstract

Objective: The aim of the study was to determine mammographic breast density changes during raloxifene therapy in post­menopausal patients Materials and Methods: Fifty-five cases who were using raloxifen therapy were included in this retrospective analysis. Ralox-1fene was given for osteopenia and osteoporosis according to low bone mineral density measured by dual-energy X-ray absorp­tiometry (DEXA). None of the patients were using hormone replacement therapy 12 months before the initiation of raloxifene treat­ment or during the study. Mammographic breast density was determined by mammography before the initiation of raloxifene treatment (baseline) and after 12 to 16 months of therapy. The Breast Imaging Reporting and Data System (BI-RADS) breast density score was used for the evaluation of mammographic density. Results: There was no change in mammographic breast density when the baseline and the first mammography taken after the ini­tiation of therapy were compared (p = 0.32). There was no significant correlation between the duration of raloxifene treatment and mammographic density measured after raloxifene treatment (r = -0.158, p = 0.25). Only in one patient did the BI-RADS classifi­cation of 2 change to 3 after 12 months of therapy Conclusions: In conclusion, raloxifene therapy for 12 to 16 months does not increase mammographic breast density in post­menopausal women with low bone mass.

Keywords
Breast cancer
Mammography
Raloxifene
Share
Back to top